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ABSTRACT 
 
Migraine is a complex polygenic disorder that continues to be a great source of morbidity in the 
developed world with a prevalence of 12% in the Caucasian population.  Genetic and 
pharmacological studies have implicated the glutamate pathway in migraine pathophysiology.  
Glutamate profoundly impacts brain circuits that regulate core symptom domains in a range of 
neuropsychiatric conditions and thus remains a “hot” target for drug discovery.  Glutamate has 
been implicated in cortical spreading depression (CSD), the phenomenon responsible for migraine 
with aura and in animal models carrying FHM mutations.  Genotyping case-control studies have 
shown an association between glutamate receptor genes, namely, GRIA1 and GRIA3 with 
migraine with indirect supporting evidence from GWAS.  New evidence localizes PRRT2 at 
glutamatergic synapses and shows it affects glutamate signalling and glutamate receptor activity 
via interactions with GRIA1.  Glutamate-system defects have also been recently implicated in a 
novel FHM2 ATP1A2 disease-mutation mouse model.   Adding to the growing evidence 
neurophysiological findings support a role for glutamate in cortical excitability.  In addition to 
the existence of multiple genes to choreograph the functions of fast-signalling glutamatergic 
neurons, glutamate receptor diversity and regulation is further increased by the post-translational 
mechanisms of RNA editing and miRNAs.  Ongoing genetic studies, GWAS and meta-analysis 
implicate neurogenic mechanisms in migraine pathology and the first genome-wide associated 
locus for migraine on chromosome X.  Finally, in addition to glutamate modulating therapies, the 
kynurenine pathway has emerged as a candidate for involvement in migraine pathophysiology.  
In this review we discuss recent genetic evidence and glutamate modulating therapies that bear on 
the hypothesis that a glutamatergic mechanism may be involved in migraine susceptibility.  
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1. Glutamatergic Mechanisms in Migraine 
There has been ongoing interest in the involvement of glutamate in migraine pathophysiology.  
Biochemical studies of migraine patients have shown significant differences of glutamate in a 
range of biological fluids relative to controls, particularly in migraineurs with aura (1-3).  Evidence 
for this idea, the ‘glutamate hypothesis’, was discussed by Ramadan (4) and more recently 
Gasparini (5).  The glutamate hypothesis of migraine is centered on the subset of pathologic 
mechanisms linked to glutamatergic signaling and is based on genetic, biochemical and clinical 
findings pointing to a hypofunction of glutamatergic signaling (6).  Glutamate is a ubiquitous 
neuro-messenger that can be likened to a ‘handle with care explosive’ stored in intracellular 
vesicles at high concentration (10mM) and is a key player in numerous metabolic pathways (7).   
 
Glutamate is toxic to neurons in the brain can kill them when it persists in and around synapses, 
and is also able to initiate migraine by cortical spreading depression (CSD) the lynchpin of 
migraine aura (8-10).  CSD has been studied experimentally and waves of CSD promoted by a 
wide range of stimuli including local mechanical stimulation, local injury, high frequency 
electrical pulses, potassium chloride, potassium ions, hypo-osmotic medium, metabolic inhibitors, 
ouabain, glutamate receptor agonists, glutamate, acetylcholine and endothelin (11, 12).  These 
noxious stimuli perturb the neuronal environment leading to glutamate-induced excitotoxicity.  
During CSD, glutamate contributes to a loss of membrane potential and disruption of ionic 
gradients (Ca2+, Na+, K+) (13, 14).  Ca2+ and Na+ channels, as well as glutamatergic and/or 
GABAergic transmissions are active in CSD and targeted by antiepileptic drugs (9).  N-methyl-D-
aspartate (NMDA) receptors, which are activated by glutamate, play an essential role in CSD 
mechanisms and antagonists of NMDA receptors have been shown to reduce CSD (15, 16).   
 
Poor glutamate processing results in a build-up of extracellular glutamate which is toxic to neurons 
(17).  Overstimulation of glutamate receptors triggers a flood of Ca2+ into cells which leads to 
uncontrolled continuous depolarization of neurons, a toxic process termed excitotoxicity first 
introduced by Olney (18).  Unregulated Ca2+ influx in turn activates a destructive cascade of events 
that triggers a number of enzymes, including phospholipases, endonucleases, and proteases such 
as calpain which destroy cell structures and components of the cytoskeleton, membrane, and DNA 
leading to the demise of the cells (19).  This situation can occur when not enough glutamate 
transporters are present to clean up the extracellular spaces or transporters are sluggish because of 
CNS injury or genetic defects that decrease the functionality of glutamate transporters.  Alterations 
in the expression, distribution, synaptic levels, recycling and autoregulation of glutamate receptors 
and transporters can result in altered glutamatergic function (20). 
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2. Glutamate Genetic Evidence 
Glutamate action is governed by a number of genes involved in its reception; transport and 
synthesis (see Table 1).  Interest in the role of glutamate in migraine at the molecular genetic level 
was instigated by Formicola et al., in 2010 who reported an allelic association between intronic 
variants of the GRIA1 and GRIA3 AMPA receptor gene subunits and migraine with aura (21).  
Since this initial study a handful of subsequent studies have examined the relationship between 
glutamatergic dysfunction and migraine.  Notably, a replication study by Maher et al., (22) 
identified association in 1 of 3 GRIA3 polymorphisms (rs3761555) and none of the GRIA1 variants 
tested in the Formicola et al. study (21).  The positive association was observed in the GRIA3 
promoter polymorphism (rs3761555) (22) in an Australian case-control cohort of 500 migraineurs, 
this is double the size of the Italian population (250 migraineurs) used in the study by Formicola 
(21).  The GRIA3 SNP is in a promoter binding site and the T allele, which was over-represented 
in the Australian case cohort, reduces the promoter activity and therefore affects the expression of 
the gene (22).  In addition a positive association between the X-linked gene, GRIA3 (rs1034428, 
A allele) and schizophrenia was reported in female patients (23).  These results are supported by 
studies by Ibrahimetal et al., (24) and by Meador-Woodruffetal et al., (25) reporting decreased 
expression levels of the AMPA receptor.   
 
Two studies, one by Gasparini et al., (26) and a study by Cargnin et al., (27) genotyped 
polymorphisms in the GRIA2 and GRIA4 genes in an Australian case-control cohort and in the 
GRIA1 gene in an Italian case-control cohort, respectively.  Although both these studies indicated 
that GRIA genotypes and haplotypes did not influence migraine susceptibility, a recent study by 
Fang et al., 2015 (28) detected an association of GRIA1 (rs2195450) to female migraine (MA, 
MO) susceptibility in the Chinese Han population.  Investigation into other glutamate related genes 
have also shown connections with migraine. The activity of the enzyme glutamate oxaloacetate 
transaminase (GOT) was shown to be reduced in blood in a case-control study of 45 episodic 
migraine patients and 16 control subjects (20).  Recently mutations in glutamate receptor genes 
have also been reported for their involvement in the aetiology of epilepsy, intellectual disability 
and mental retardation (29-33).   In addition to the genetic evidence, biochemical studies add 
credence to a glutamatergic mechanism for migraine reviewed in Gasparini et al., 2015 (5). 
 
Imbalance in glutamate regulation including glutamate release and clearance, has also been 
postulated in the pathogenesis of familial hemiplegic migraine, (FHM), whereby mutations in 
causal ion channel genes CACNA1A, ATP1A2 or SCN1A  are linked to neuronal excitability and 
have been correlated with increased glutamate (34-38). In the last few years the PRRT2 gene 
(proline rich transmembrane protein 2) has attracted attention due to reports of heterozygous 
mutations in the PRRT2 gene identified in patients diagnosed with hemiplegic migraine and other 
forms of migraine (39-42).  PRRT2 is also a candidate gene for epilepsy, contributing to a broad 
range of seizure subtypes (43).  PRRT2 encodes a protein distributed in brain and spinal cord that 
is predicted to regulate presynaptic release of neurotransmitters in a calcium-triggered process that 
also requires synaptosomal associated protein 25 (SNAP-25) (44, 45).  Heron et al., pointed out 
that perturbation of this process due to mutations in the PRRT2 gene is likely to be the cause of 
seizure and movement disorder phenotypes including paroxysmal kinesigenic dyskinesia (PKD), 
benign familial infantile epilepsy (BFIE), infantile convulsions and choreoathetosis (ICCA) and 
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hemiplegic migraine (HM)  (46).   PRRT2 has thus been dubbed “a gene with remarkable 
pleiotropy” due to its involvement in a spectrum of paroxysmal neurological disorders. 
 
Interestingly, a recent study by Li et al., demonstrated that PRRT2 is located at glutamatergic 
synapses by double immunostaining neurons of mouse cortex with a pre-synaptic marker (vGlut1) 
and a post-synaptic marker (PSD-95) of glutamatergic neurons (47).  Greater levels of PRRT2 
expression were demonstrated in this study in the mouse cerebral cortex, hippocampus and 
cerebellum (48).  They also showed that wild type PRRT2 remains anchored in the membrane 
whilst mutated PRRT2 detaches and disperses in the cytoplasm of COS-7 cells.  The authors 
confirmed interactions between PRRT2 and SNAP-25 as previously demonstrated and that these 
are disturbed by the presence of mutations in PRRT2 (47, 49).  The SNAP-25 protein participates 
in the regulation of synaptic-vesicle exocytosis and association studies have suggested that some 
SNAP-25 gene polymorphisms may be implicated in psychiatric diseases including schizophrenia 
and attention deficit hyperactivity disorder (50, 51).  Most importantly, the authors demonstrated 
protein-protein interactions between mouse PRRT2 and GRIA1 both in vitro and in vivo and that 
these were weakened in the presence of mutant PRRT2.  GRIA1 is 1 of 4 subunits that assemble 
to form the ligand-gated AMPA receptor which is integral to fast excitatory transmission and 
common variants in the GRIA1 gene have previously been associated with migraine patients with 
and without aura (21, 52).  PRRT2 knock down gene expression with shRNA-PRRT2 lentivirus 
resulted in increased glutamate levels in neural cell culture.  This was the first study to verify that 
PRRT2 can affect glutamate signalling and glutamate receptor activity and that this event may be 
connected with neuronal hyperexcitability (47).  
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Table 1 Gene and Protein Constituents of the Glutamatergic System adapted from (53). 
 
Gene Name Protein - Enzymes 
PDP1 PDH, Pyruvate dehydrogenase 
GLS2 PAG, Phosphate activated glutaminase 
ME3 mME, Mitochondrial malic enzyme 
GAD1 GAD, Glutamic acid decarboxylase 
GLUL GS, Glutamine synthetase 
PC PC, Pyruvate carboxylase 
ME1 cME, Cytosolic malic enzyme 
GOT1 AAT, Aspartate aminotransferase 
GLUD1 GDH, Glutamate dehydrogenase 
Gene Name Protein - Ionotropic glutamate receptors (iGluRs) Antagonists 
GRIA1 AMPA BGG492 
GRIA2 AMPA LY293558 
AMPA/kainate 
GRIA3 AMPA  
GRIA4 AMPA  
GRIK1 Kainate LY466195 
GRIK2 Kainate  
GRIK3 Kainate  
GRIK4 Kainate  
GRIK5 Kainate  
GRIN1 NMDA Memantine 
GRIN2A NMDA Ketamine 
GRIN2B NMDA Topiramate 
AMPA/kainate 
GRIN2C NMDA  
GRIN2D NMDA  
GRIN3A NMDA  
GRIN3B NMDA  
GRID1 Orphan  
GRID2 Orphan  
Gene Name Protein - Metabotropic glutamate receptors 
(mGluRs) 
Antagonists 
GRM1 mGluR1  
GRM2 mGluR2  
GRM3 mGluR3  
GRM4 mGluR4  
GRM5 mGluR5 ADX10059 
GRM6 mGluR6  
GRM7 mGluR7  
GRM8 mGluR8  
Gene Name Protein - Transporter Type Antagonists 
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SLC1A3 EAAT1  
SLC1A2 EAAT2  
SLC1A1 EAAT3  
SLC1A6 EAAT4  
SLC1A7 EAAT5  
SCL17A7 VGLUT1 Botulinum toxin type A 
SCL17A6 VGLUT2 Lamotrigine 
SCL17A8 VGLUT3  
 
Note:  Some enzymes are composed from individual subunits that assemble to form larger 
multimeric complexes and therefore the same enzyme name will appear to have multiple 
chromosomal locations in the databases.   
 
 
 
 
3. Novel FHM2 ATP1A2 disease-mutation mouse model  
 
Perturbed glutamate neurotransmission is demonstrated in a myriad of psychiatric diseases 
including schizophrenia, Parkinson’s disease, Alzheimer’s disease, epilepsy and diseases of 
addiction (54, 55).  Models are needed to characterize and explore the key molecular events at the 
core of the neurobiological base of neuropsychiatric disorders.  Animal models are useful for two 
main reasons: one is to study the pathophysiology and progression of a disease and second to 
identify and validate drug targets and for developing and testing new drugs for use in human 
patients (56).  Models of glutamate involve studying glutamatergic signalling and up until now, 
have focussed on glutamate excitotoxicity induced by acute exposure of neurons, either in vitro or 
in vivo, to sudden large excesses of extracellular glutamate (17).  Cell model systems have been 
used to study glutamate excitotoxicity and in particular the end result of activating intracellular 
signaling cascades initiated by the excitotoxic insult (57).  In addition, cloning of the receptors has 
enabled the expression of proteins in expression systems, Xenopus oocytes or in mammalian cell 
lines for biochemical characterization, structure analyses, subunit composition and 
electrophysiological studies (57).  Pharmacological models of the single receptors can help derive 
knowledge of structure-function relationships and of glutamate function, kinetics of response, 
different doses, downstream signaling (58, 59).  In recent times, X-ray crystal structures of 
glutamate receptors have helped deﬁne structure-function relationships based upon co-crystals of 
the ligand-binding for a myriad glutamate receptors as well as with positive allosteric modulators 
(57, 60-62).  These studies have provided insight into the mechanism of action of glutamate 
receptor antagonists and the molecular interactions between receptor and modulator.  Finally, 
animal localization studies have also identified NMDA, AMPA, Ka receptors in the trigeminal 
system (63, 64).   
 
Recently Bottger et al., 2016 described a completely novel familial hemiplegic migraine (FHM), 
FHM2 disease-mutation mouse that exhibits glutamate-system defects and psychiatric 
manifestations, mood depression and obsessive-compulsive disorder (OCD) (65).  FHM2 (FHM2; 
MIM602481) is a rare form of migraine with hemiplegia and partial paralysis during the aura phase 
and, in some cases, accompanied by seizures or cognitive dysfunction (35).  Familial hemiplegic 
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migraine (FHM) is a disorder that lends itself more easily to functional analysis in animal models 
due to well characterized mutations in large effect genes.  FHM2 is caused by mutations in 
the ATP1A2 gene.  The ATP1A2 gene encodes the α2 isoform of the major subunit of the Na+/K+-
ATPase pump and is located at 1q21-23 (35).  The product of the ATP1A2 gene is a sodium-
potassium pump (α2Na+/K+-ATPase) that aids in establishing and maintaining the electrochemical 
gradients of Na+ and K+ ions across the plasma membrane of astrocytes.  Mutations in 
the ATP1A2 gene were first identified in two Italian families in 2003 and account for 
approximately 20% of FHM in families (66, 67). 
 
Most recently in the Lykke-Hartmann lab, Bottger et al., introduced the FHM2-associated G301R-
mutation in knock-in mice (65).  This new knock-in mouse builds upon previous work, including 
two separate groups, the Lingrel lab (68) and Kawakami lab (69) who created FHM2 knock-outs 
through disruption of the ATP1A2 gene at two different locations, exon 4 and exon 21 respectively.  
Conversely the Casari lab generated the first FHM2 knock-in mouse by inserting the T2763C 
mutation, which causes the amino acid substitution W887R in exon 19 of the gene (70).  In cell-
based studies, a complete loss of pump function is observed due to misfolding of the protein in the 
β subunit binding site (71).  The Lykke-Hartmann lab is the second group to create an FHM2 
knock-in mouse (65).  Mice heterozygous for the FHM2-associated G301R-mutation show 
impaired glutamate uptake in in vitro hippocampal-derived matured mixed cultures of astrocytes 
and neurons established from embryos (E17) compared to WT mice.  Following a series of 
behavioural tests the mice were found to suffer stress-induced depression and reduced sociability.  
The observed behavioural phenotypes are thought to be linked to ineffective handling of glutamate 
in the synaptic cleft and seem to be more pronounced in female mice α2+/G301R due to an interplay 
with the female sex hormone cycle.   
 
In addition pharmacological treatment of mice with NMDA receptor antagonists, amantadine and 
memantine, which act to decrease NMDA receptor signalling, was found to rescue marble burying 
behaviour.  Marble burying is typically used as a measure of compulsive behaviour of OCD, and 
in this instance amantadine and memantine counteracted the glutamate-system defects induced by 
the presence of the mutation in the ATP1A2 (65).  Electrophysiological recordings demonstrated 
prolonged recovery phase after induction of CSD in males due to compromise and impairment of 
Na+/K+-ATPase pump activity.  This is in line with other FHM mutations where the phenomenon 
CSD has been studied and glutamate has been implicated (72).  FHM gene mutations play a role 
in synaptic transmission and brain excitability by affecting the neuronal current and facilitating 
CSD ignition in FHM (38, 73, 74).  Deregulated handling of glutamate is hypothesised to play a 
role in facilitating CSD due to increased probability of glutamate release as shown in FHM1 
R192Q, S218L knock-in mice (37, 72).  Recently new evidence from a transgenic mouse model 
of migraine, reveals that CSD in addition to initiating a series of neural and vascular events can 
also modulate inflammatory processes (75).  In the cortex of FHM1 R192Q mutant brains, specific 
genes in interferon-mediated inflammatory signalling were shown to be up-regulated in response 
to CSD (75).  Altogether these results are novel and add to our current understanding of FHM and 
migraine and co-morbid psychiatric manifestations.   
 
In the future with the advent of the genome-editing toolbox, using transcription activator-like 
effector nucleases (TALEN) or clustered regularly interspaced short palindromic repeats that rely 
on RNA-guided DNA endonuclease Cas9 (CRISP/Cas9) in mammalian cells will surely be 
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exploited for functional studies based on GWAS findings to generate cellular and animal models 
in a more efficient manner.  Innovative methods such as non-viral (siRNA) or viral (shRNA) 
delivery techniques may enable more subtle genetic manipulations.  These methods can achieve 
more sensitive down-regulation or completely silencing genes in more subtle ways than by 
complete knock-down.  These can be useful to study time dependent gene expression and can be 
engineered in all cells of the body or in a tissue specific manner and may be manipulated to alter 
their activity in response to specific stimuli.   
 
 
 
4. Neurophysiological Evidence 
 
The aim of neurophysiology studies was originally to aid in diagnosis and then characterization of 
cortical excitability in the migraine brain in the search for biomarkers (76).  Cortical excitability 
refers to the reactivity of the brain to diverse exogenous and endogenous stimuli and is measured 
as the “global output of cortical neurons to external stimuli” (77, 78).  Neurophysiological 
interactions are typically assessed by techniques that measure the excitability of the brain and 
include evoked potentials (EPs) techniques and non-invasive brain stimulation methods such as 
transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) (79).  
Most studies support changes in cortical excitability throughout the migraine cycle and that 
migaineurs display an impairment of habituation to repeated sensorial stimulation which may 
represent a neurophysiological marker of migraine (77, 80-82).  Deficit of habituation seems to be 
the most consistent response found in migraineurs for many stimulation modalities: visual, 
auditory and somatosensory (83).  Habituation is a behaviour that refers to the inability of migraine 
patients to habituate or adapt to repeated sensory stimulation (84).  The goal of studies measuring 
visual evoked potentials (VEPs) in migraine is to determine if specific alterations in visual function 
may be present.  Many of these studies have reported that different subgroups of migraineurs, in 
particular those with migraine with aura, have distinct visual evoked potential profiles and a lack 
of habituation (85-90).  Recently a study assessed differences of pattern-reversal visual evoked 
potential parameters and migraine in a teenage migraine with aura and without aura cohort (91).  
In this cohort, migraine with aura patients had longer N2 wave latencies relative to migraine 
without aura patients and healthy controls. Results have not always been consistent and a clear 
consensus regarding habituation, which was considered to be a neurophysiological hallmark of 
migraine, is lacking.  This has been attributed to sources of methodological heterogeneity that 
prevent exact conclusions to be drawn.  In addition, migraine is a multifaceted and cycling disease 
and the type of migraine studied and the stage of illness can also have a bearing on the results 
obtained.  
 
The level of neuronal excitability (excited or inhibited) is determined by multiple neurotransmitter 
systems including glutamate-dopamine-serotonin which converge in their signalling circuits and 
cellular receptors (92).  The trio of primary neurotransmitters including serotonin, dopamine, and 
glutamate affect each other in complex ways, overlapping in their neurotransmitter circuits and 
hyperactive glutamate neurotransmission may account for the dysfunctions observed in migraine 
(see Figure 1).  Glutamate and its actions on N-methyl-d-aspartate (NMDA), and non-NMDA 
receptors facilitates excitation (93).  Certain groups support glutamatergic dysfunction as the 
culprit of cortical excitability (81, 94, 95).  In summary, neurophysiological studies have shown 
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evidence of cortical dysfunction and a deficit of habituation to repeated stimuli that fluctuates with 
the migraine cycle.  Moreover, a disequilibrium between intracortical inhibitory and excitatory 
neuronal circuits (96) is present in the migraine brain and neurophysiological testing may help 
reveal additional clues to understand brain dysexcitability.  Inconsistencies in results, however, 
still leave some questions in this area to be answered. Future studies will need to replicate one 
another and arrive at standardised methodologies in order to further our neurophysical 
understanding of migraine. 
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Figure 1 Neurotransmitter Systems implicated in Migraine adapted from (97).   
 
Genetic, biochemical and pharmacological studies support the involvement of the neurotransmitters serotonin, dopamine and glutamate 
in migraine aetiology.  Genetic studies have focused on the receptors, transporters and enzymes involved in the synthesis and metabolism 
of neurotransmitters.  Genetic variation in the gene constituents of neurotransmitter systems may cause dysfunctional signalling and 
neurotransmission leading to an imbalance in the way the neurotransmitter is handled at the synapse ie., released and recycled and may 
lead to a higher susceptibility to migraine.  The hypothesis is based on the idea that disturbances in circulating levels of neurotransmitters 
or in the function of the receptors, transporters and enzymes that synthesise and metabolise the neurotransmitters due to an aberrant 
combination of genes may express the biochemical phenotype of migraine.   
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5. RNA editing of AMPA glutamate receptors 
 
In addition to the existence of multiple genes to choreograph the functions of fast-signalling 
glutamatergic neurons, glutamate receptor diversity is further increased by the post-translational 
mechanisms of alternative splicing and RNA editing (98).  Adenosine-to-Inosine (A-to-I) RNA 
editing of the GRIA2 subunit of glutamate AMPA receptors at the coding region 
glutamine/arginine (Q/R607) site (in the pore forming second transmembrane (M2) domain) 
epitomizes genetic regulation of glutamate receptors (99).  The Q/R site of the GRIA2 subunit 
undergoes extensive (>99.9%) editing and this editing is important for gating Ca2+ entry through 
the AMPA receptor channels (100, 101).  In a healthy state, effective RNA editing at the Q/R site 
results in the production of GRIA2-(R) (arginine amino acid) whilst in a diseased state, defective 
RNA editing at the Q/R site results in the production of GRIA2-(Q) (glutamine amino acid) (102). 
Inefficient editing of the GRIA2 subunit results in AMPA glutamate receptor channels that are 
permeable to Ca2+ (103), resulting in cell death due to flooding with Ca2+ and this event has been 
linked to the disease amyotrophic lateral sclerosis (ALS) (104, 105).  Targeted RNA editing also 
controls the heteromeric assembly of the AMPA receptors by holding the GRIA2 subunits in the 
endoplasmic reticulum and delaying transport to the synaptic surface (106).  Consequently RNA 
editing at this site is an essential mechanism that indirectly contributes to the effective functioning 
of glutamatergic neurotransmission.  RNA editing is an enzymatic process that is carried out by 
two enzymes of the adenosine deaminase family ADARB1 and ADARB2 that mostly target 
neurotransmitter receptors and ion channels (107).  These two genes have also been investigated 
as plausible candidates in migraine (108) because they are most prevalent in the central nervous 
system and fit criteria for migraine neuropathology (109).  Further illustrating the importance of 
these two RNA-editing enzymes ADARB1 knockout mice die approximately 20 days post-birth 
and manifest epileptic seizures (99) whilst ADARB2 knockout mice die embryonically, exhibit a 
high interferon signature, increased apoptosis and hematopoietic defects (110-112).  Additionally 
a few studies suggest a role for ADARB1 in the pathophysiology of mental disorders (113, 114). 
 
6. miRNAs and Implications for Migraine 
 
Introducing another dimension to current migraine research is modification of gene expression via 
microRNAs (miRNAs).  miRNAs are small non-coding RNA molecules (19–24 nucleotides) 
encoded in our genome that modulate gene expression by actively targeting mRNAs post-
transcriptionally (115).  miRNAs interact with mRNAs by complementary binding by different 
mechanisms to inhibit their translation and expression of the encoded genetic information (116).  
They act like silencing tags that regulate genome activity and protein levels and thus fine tune 
numerous modalities of the cell including differentiation, proliferation, apoptosis in symphony 
with other gene regulatory processes (117).   
 
The extent to which miRNAs are involved in brain development and in the aetiology of neuro-
psycho and degenerative disorders remains to be quantified.  miRNA expression has been studied 
in a variety of neurological disorders including Alzheimer’s, Parkinson’s, and Huntington’s 
diseases, amyotrophic lateral sclerosis epilepsy (118) (119, 120), schizophrenia, autism, cognitive 
dysfunction and drug addiction (121).  Recently miRNAs have been implicated in bipolar disorder 
(122, 123) and it is not unlikely that these regulatory RNAs might have some usefulness in 
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migraine diagnosis as well.  miRNA are important regulators of gene expression with important 
functions, yet to be understood, in brain development and in regulating many aspects of neuronal 
morphology, such as neurite outgrowth and synapse formation (124).  miRNAs display a  brain-
specific expression pattern and the majority of proteins are regulated by miRNAs (125, 126).   
 
A point in case is miRNA regulation of the main CNS glutamate transporter EAAT2/GLT1 of the 
glutamatergic system.  In 2013, Morel et al., demonstrated that exogenously delivered miR-124a 
can up-regulate EAAT2 (excitatory amino acid transporter 2) protein expression both in vitro and 
in vivo (127).  This is an interesting finding with potential to be turned into a therapy to regulate 
EAAT2 activity in disease states and in addition reveals a novel regulatory mechanism.  In a study 
by Harraz et al., miR-223 was reported to regulate the expression of AMPAR subunit GluR2 and 
NMDAR subunit NR2B 3-UTR (128).  miR-223 deficiency increases expression of GluR2 and 
NR2B and consequently miR-223 is a key regulator of glutamate receptor expression and function.  
There are other examples whereby miRNAs have been shown to regulate NMDA receptors in 
schizophrenia and other conditions but it is beyond the scope of this review (129, 130).   
 
Thus far two studies have directly explored the nexus between miRNAs and migraine.  Anderson 
et al., profiled microRNAs using serum from migraine sufferers during attack periods and pain-
free periods, comparing these to healthy control subjects (131).  This study identified four 
microRNAs to be differentially expressed out of 372 (miR-34a-5p, miR-29c-5p, miR-382-5p and 
miR-26b-3p) and these were selected for further investigation (131).  Expression of these miRNAs 
was significantly altered between migraineurs and healthy controls in two independent validation 
cohorts (n = 16 and n = 24).  The authors could not account for the structures/tissues from which 
the miRNAs originate, however in silico target predictions suggested the miRNAs may target 
components of GABAergic and anti-inflammatory signalling pathways.  The second study by Tufi 
et al. (132) in contrast, screened 175 miRNAs most commonly detected in plasma exosomes and 
analysed the expression of miRNAs in the blood of 15 MO patients and matching controls by qRT-
PCR.  In this study four miRNAs were differentially expressed: miR-27b was significantly up-
regulated, while miR-181a, let-7b, and miR-22 were significantly down-regulated.  The miRNAs 
reported in this study appear to have some connection with cardiovascular disease and may provide 
a circulating exosome miRNA profile specific to MO patients. 
 
The significance and relevance of this layer of genetic regulation on the occurrence of migraine 
remains to be discerned.  Currently there is insufficient data to correlate a definite relationship 
between miRNAs and migraine.  From the evidence of involvement of miRNAs in other diseases 
co-morbid with migraine like epilepsy, however, it is clear these regulatory molecules may hold 
potential to be used as migraine biomarkers.  Although miRNA research is still in its infancy the 
field is blossoming with an increase in the number of biomarker studies investigating the potential 
use of miRNAs as a diagnostic tool in different biological fluids for different neurological 
disorders (133).    This is due to the fact that miRNAs are found in all body tissues and fluids such 
as plasma, serum, urine, saliva, milk and CSF and different organs express different miRNAs, 
allowing specific profiles to be obtained (134, 135). 
 
 
15 
 
7. GWAS 
 
Additional associations in SNPs located in genes that act to regulate glutamate turn over have been 
uncovered in Genome Wide Association Studies (GWAS).  Comprehensive GWAS studies have 
been instrumental in revealing a number of interesting and novel potential candidate loci without 
a priori assumptions that implicate glutamate in migraine aetiology (136-138).  The main hit from 
the first migraine GWAS was an intergenic SNP (rs1835740) at locus 8q22.1 identified in 
migraineurs from three European headache clinics that is in linkage disequilibrium (LD) with two 
candidate genes: plasma glutamate carboxypeptidase (PGCP) and; the astrocyte elevated gene 1 
(MTDH/AEG-1) (136).  The enzymatic function of the PGCP gene is to cleave N-acetyl-l-aspartyl-
l-glutamate into N-acetyl aspartate (NAA) and glutamate and via this function PGCP may 
contribute to a rise in extracellular glutamate concentrations (139).  Meta-analysis of GWAS 
results by Ligthart, et al., replicated the association with the MTDH/AEG-1 gene (138).  In cultured 
lymphoblastoid cell lines the risk allele A of SNP rs1835740 was found to correlate with the 
transcript levels of MTDH/AEG-1.  Furthermore, experiments in cultured astrocytes documented 
an inverse correlation between expression levels of MTDH/AEG-1 and EAAT2 (140-142).  
MTDH/AEG-1 can decrease the expression of the glutamate transporter EAAT2 (also called GLT1 
and SLC1A2) in neurons and this fault is thought to lead to excess glutamate in the synapse which 
could potentiate migraine by making cells more susceptible to glutamate excitotoxicity (143, 144).  
 
More recently, a study by Lee et al. (145) provided evidence of the ability of MTDH/AEG-1 to 
downregulate the expression of EAAT2 in the setting of glioma-induced neurodegeneration.  The 
proposed pathological mechanism is that too much glutamate in the synaptic cleft due to an 
increase in PGCP activity or MTDH/AEG-1 or both may contribute to migraine attacks.  EAAT2 
is the major transporter of glutamate in neurons whose importance to neural biology is further 
exemplified in knockout mice.  The lack of functional EAAT2 produces a fatal phenotype leading 
to progressive neurodegeneration and spontaneous epileptic seizures (146-148).  Glutamate 
transporters serve critical physiological functions such as terminating fast synaptic 
neurotransmission and as such they are subject to tight spatio-temporal expression and regulation 
(149).  In addition mutations in the related EAAT1 transporter have shown up in other episodic 
disorders such as episodic ataxia 6 (150, 151), and a non-familial hemiplegic migraine type 1 or 2 
(FHM1/2) hemiplegic migraine/episodic ataxia/seizure phenotype (152).   
 
In a GWAS by Chasman et al., 2011, the three most significant GWAS hits that reached genome-
wide significance and withstood replication in three replication data sets were rs2651899 in 
PRDM16, rs10166942 in TRPM8 and rs11172113 in LRP1 (137).  The proteins produced by 
PRDM16 (PR domain containing 6), TRPM8 (transient receptor potential melastatin 8) and LRP1 
(low density lipoprotein receptor 1) indirectly affect glutamate turnover.  The product of the 
PRDM16 gene is involved with the development of brown fat but its function and relation to 
migraine aetiology remains to be established (153).  TRPM8 is an ion channel related to 
neuropathic pain but its complete range of functions is not fully understood (154).  The LRP1 
protein has been found to interact with N-methyl-D-aspartate (NMDA) receptors, suggesting a 
more direct role in the glutamate pathway providing support for a glutamatergic mechanism in 
migraine (137, 155).  Two of the loci, rs10166942 in the TRPM8 gene and rs11172113 in the LRP1 
gene identified in the Chasman study were confirmed in German and Dutch individuals as being 
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involved with the MO phenotype (156).  Meta-analysis of clinic-based Danish and Icelandic 
migraineurs identified a similar association (157).   
 
Recently, replication studies in Spanish, Swedish, Chinese and Indian populations independently 
replicated some of the top-ranking SNPs from GWAS data (158-161).  Replicating GWAS hits is 
important as the risk imparted by the variants may vary and be population specific.  In the Spanish 
study nominal associations were identified for single nucleotide polymorphisms rs2651899 (within 
the PRDM16 gene), rs10166942 (near TRPM8), rs12134493 (close to TSPAN2) and rs10504861 
(near MMP16) in a migraine with aura sample (158).  In the Swedish study association in 
rs2651899 was identified (160).  The Indian study reports association in rs1835740, LRP1 
rs11172113 and PRDM16 rs2651899 polymorphisms (159).  In the Chinese Han study the 
association of PRDM16 to migraine susceptibility was reaffirmed (161).  
A recent GWAS conducted in 460 bipolar migraineurs with 914 bipolar patients without migraine 
from the Bipolar Genome Study (BiGS) identified a genome-wide significant association with 
migraine in these patients and rs1160720, an intronic SNP in the NBEA gene (162).  The NBEA 
protein plays a role in trafficking neurotransmitter receptor filled vesicles but since the association 
of this SNP did not replicate in data from the GWAS migraine meta-analysis consortium and a 
smaller sample of 289 migraine cases, the authors concluded that this may be an association 
speciﬁc to migraine co-morbid with bipolar disorder.   
 
Altogether GWAS have thus far identified 13 risk loci of genome-wide significance to modulate 
susceptibility to migraine (136, 137, 156, 163).  These loci show enriched functions in 
glutamatergic neurotransmission (MTDH, LRP1, MEF2D), neuron and synapse development 
(MEF2D, ASTN2, PRDM16, FHL5, PHACTR1, TGFBR2 and MMP16), brain vasculature 
(PHACTR1, TGFBR2, C7orf10), extracellular matrix (MMP16, TSPAN2, AJAP1), and pain-
sensing (TRPM8) supporting neurogenic mechanisms (164).  These findings are corroborated by 
another recent GWAS implicating astrocytes and oligodendrocytes in migraine pathophysiology 
with different genetic backgrounds for MA and MO (165).  Functional and biochemical 
characterization of these proteins will be needed to further decipher their involvement in migraine 
processes.  Despite GWAS proving to be a powerful tool to identify genes of small effect sizes it 
does not answer questions about disease-mechanisms, nor gene expression or biochemical 
questions to inform the underlying processes of a disease.   
 
Based on the generally accepted view that “functionally related genes show coordinated expression 
in order to perform their cellular functions” (166) a recent GWAS used two statistical methods to 
identify modules of gene expression to identify brain regions, cell types and pathways involved in 
migraine pathophysiology (167).  In this GWAS based study the authors used gene expression data 
from the Allen Human Brain Atlas enriching for migraine associated genes.  Secondly, drawing 
from the largest migraine GWAS dataset currently available (Anttila et al. 2013) they used high-
confidence migraine genes to build a migraine-related co-expression gene network (167).  
Importantly, this study highlighted genes involved in mitochondrial function and common 
migraine which is not surprising given that synapses of neurons are regions of high energy demand 
and abundant in mitochondria (168).  Glutamatergic alterations and mitochondrial impairments 
are closely interrelated (169-172).  Mitochondrial variants were hypothesized to be involved in 
migraine after morphological, biochemical, imaging and genetic studies identified some 
mitochondrial abnormalities that may be related to mitochondrial dysfunction at least in some 
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individuals (173-177).  Noteworthy is a study Zaki et al., who identified two polymorphisms in 
the mitochondrial genome, C16519T and G3010A, associated with migraine and cyclic vomiting 
syndrome CVS (174).  In addition, recently an association for a locus in the mitochondrial 
DNA with migraine, both with and without aura was reported by Guo et al. (178), and Anttila et 
al., for a mitochondrial ATP synthase, ATP5B  (179).   
 
Most recently the largest meta-analysis of migraine consisting of 59,674 cases and 316,078 
controls of European ancestry identified 38 susceptibility loci that map to factors in vascular and 
smooth muscle tissues for migraine from 22 GWA studies (180).  Not surprisingly, ten of the 13 
GWAS hits identified in this meta-analysis replicate previous GWAS results (180).  Surprisingly, 
only two of 38 genomic loci are in ion channel genes (KCNK523 and TRPM824) and three other 
loci (SLC24A326, ITPK127, and GJA128) are involved more generally in ion homeostasis (180).  
This result is in contrast to prevalent notions of migraine pathogenesis that support the involvement 
of ion channel genes and the grouping of migraine into a channelopathy but is in agreement with 
the idea that the expression of multiple genes of modest effect in the so called ‘migraine polygenic 
model’ perpetuates the migraine phenotype (181).   
 
 
8. X Chromosome 
 
The meta-analysis by Gormley et al., 2015 also identified the first genome-wide associated locus 
for migraine on chromosome X (180).  This finding is in line with previous genetic studies of the 
X chromosome which have implicated three distinct susceptibility loci at Xp22, Xq13, Xq24-28 
with stronger evidence in support of the Xq24-q28 region (182-184).  The hypothesis that genomic 
factors on the X-chromosome may play a part in migraine aetiology is due to the uneven gender 
distribution observed in epidemiological data (gender ratio 3:1 of female migraine sufferers) (185, 
186).  In particular, the observed female preponderance is ascribed to hormonal influences which 
correlate with reproductive milestones and possible gene dosing effects, as females inherit two 
copies of the X chromosome while males only inherit one X.  In addition, the proportion of male 
probands with affected first-degree relatives is notably higher with respect to relatives of female 
probands (187). 
 
Although a number of candidate genes in the Xq24-Xq28 region including 5-hydroxytryptamine 
(serotonin) receptor 2C (5HT2C), Glutamate Receptor ionatropic AMPA3 (GRIA3), gamma-
aminobutyric acid A receptor epsilon (GABRE), gamma-aminobutyric acid receptor theta 
(GABRQ) and gamma-aminobutyric acid A receptor 3 (GABRA3) have been investigated for 
association with migraine in a number of ethnically different populations (188-191), apart from 
the GRIA3 subunit of AMPA glutamate receptors at Xq24 implicated in an Italian migraine cohort, 
no specific causal gene on the X chromosome has yet been identified (21).  Interestingly, a 
common theme that links all these candidate genes together is that they have a neurological role 
and belong to the neurotransmitter class of genes supporting current concepts of neurological 
dysfunction in migraine.   
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9. Glutamate Modulating Therapies 
 
Glutamate profoundly impacts brain circuits that regulate core symptom domains in a range of 
neuropsychiatric conditions and thus remains a “hot” target for drug discovery.  Current 
evidence that supports a role of the glutamatergic system in migraine comes from randomized 
controlled trials of modulators of glutamatergic signalling and biochemical studies since the 
early 1990s that have identified increased levels of glutamate in CSF or in the blood among 
migraineurs compared with controls.  Much progress has been made in characterizing, cloning 
and crystallizing the receptors and developing antagonists since the first functional ionotropic 
glutamate receptor was cloned in 1989 (192).  Despite the number of glutamate receptor subtypes, 
their varied functions, and complex neurochemistry, to date there are only a handful of 
modulators of glutamatergic signalling in preclinical development (193).  Modulators that have 
undergone preclinical development for the treatment of migraine include BGG492, LY293558, 
LY466195, ADX10059 (194-197).  FDA approved modulators of glutamatergic signalling in 
clinical use include drugs lamotrigine, ketamine, topiramate, memantine, and BoNTA (198-202).  
The upside of these compounds is that because they are neurally based they do not have the 
vasoconstrictive side-effects of other regimens and thus may benefit some patients who have 
cardiovascular risk factors or co-morbidities (203, 204).   
 
Recently the kynurenine pathway (KP) has emerged as a candidate for involvement in migraine 
pathophysiology with growing interest in the literature (205).  The kynurenine pathway 
encompasses neuroactive compounds produced from metabolism of the essential amino acid 
tryptophan (206).  Targets of KP metabolites include both ionotropic and metabotropic glutamate 
receptors and some of these molecules have recently been linked to migraine (205, 207).  Curto 
et al., 2015 report decreased levels of kynurenine metabolites in serum samples from 21 chronic 
headache patients (208).  They also suggest that biochemical studies exploring serum kynurenine 
level may be warranted in parallel with genotypic/phenotypic profiles of the kynurenine pathway 
in migraine to better understand the importance of this pathway in migraine patients (209).  
Thorough assessment of the genetic background of the KP and pharmacological interactions with 
the KP in migraine is missing and consequently if this pathway is to be targeted for migraine 
therapy more establishing studies would need to be performed.  In addition, it may be worthwhile 
to determine if an association exists between KP metabolites, mitochondrial function and 
oxidative stress in the migraine brain and if these intracellular functions are brain-specific and 
if there are regional differences between glial cells and neurons (205).   
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10. CONCLUSION 
 
Migraine is a multi-factorial genetic disorder that evolves in adulthood and whose clinical 
presentation is dependent on the patient’s genetic background and environmental factors.  In 
agreement with biochemical studies, genetic studies provide evidence that malfunctioning of the 
glutamatergic system may contribute to symptoms of migraine.  Although it is not yet determined 
if any one component of the glutamatergic system plays a dominant role in migraine aetiology 
further studies in conjunction with recent GWAS will enhance our understanding of the pathway.  
What is definite at present is that genetic data implicating the glutamate hypothesis exists and is 
growing.  The hypothesis of a glutamatergic deficit in migraine is supported by genetic evidence 
implicating SNPs in GRIA subunit genes in migraine aura patients, glutamatergic abnormalities in 
plasma, platelets, urine and CSF in migraine aura patients and FHM mutations induce CSD and 
enhance glutamate release.  Additionally, glutamate may be involved in cortical excitability and 
consequently perturbation of the glutamatergic system and other neurotransmitter systems that 
interplay at multiple levels may play a role in migraine.  Specific animal models of glutamate are 
lacking, currently the most studied are cell based models of glutamate excitotoxicity.  
Nevertheless, progress will continue, particularly with multicentre collaborations making use of 
large patient cohorts and well-defined case material.  The application of novel genome-editing 
technologies also will help harvest recent genetic discoveries in GWASs, which is needed to have 
a more complete understanding of the disease mechanisms in migraine.  The molecular 
mechanisms regulating glutamate receptor expression and function including RNA editing and 
miRNAs remain unexplored.  This represents fertile terrain for more in depth study of how the 
gene and protein constituents of the glutamatergic system are regulated that could be developed 
into therapies. Glutamate modulating therapies and the kynurenine pathway are under-investigated 
from a genetic standpoint and further study may hasten development of novel drugs for treating 
migraine.  Deciphering the glutamatergic cross-talk in the brain is central to understanding how 
disruption of glutamatergic circuits leads to neurological and psychiatric diseases.  In conclusion, 
understanding the glutamatergic system is crucial for understanding basic brain functions such as 
learning and memory which might be applicable in the research for other neurodegenerative 
disorders than migraine, where glutamatergic proteins are additionally involved.   
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